Search

Displaying results 2121 - 2130 of 10000 in total
  1. Drug

    Clopamide

    go.drugbank.com/drugs/DB13792
    Investigational

    Like thiazide diuretics, it has an aromatic sulfonamide base but with no double-ring structure.

    Categories: Low-Ceiling Diuretics, Excl. Thiazides
  2. Drug

    Ethanolamine oleate

    go.drugbank.com/drugs/DB06689
    Approved

    Ethanolamine oleate is a mild sclerosing agent. It is composed of ethanolamine, a basic substance, which when combined with oleic acid forms a clear, straw to pale yellow colored, deliquescent oleate.

  3. Drug

    Sibeprenlimab

    go.drugbank.com/drugs/DB18919
    ApprovedInvestigational

    [A274853, A274858] Sibeprenlimab is a humanized immunoglobulin G2 (IgG2) monoclonal antibody produced by Chinese Hamster Ovary (CHO) cells. … [L54633] On November 25, 2025, sibeprenlimab was granted accelerated approval by the FDA to reduce proteinuria in adults with primary IgAN at risk for disease progression.[L54628]

  4. Drug

    Tetrachlorodecaoxide

    go.drugbank.com/drugs/DB05389
    Approved

    WF10 is a chlorite-based, immunomodulating drug is developed by Nuvo Research Inc. Certain preclinical evidence and clinical pilot data suggest that WF10 may be effective in treating certain cancers. … The Corporation believes the research to-date demonstrates that WF10 acts on macrophages (a type of white blood cell) by modulating the balance between inflammation and phagocytosis, a state in which the

  5. Drug

    Tasonermin

    go.drugbank.com/drugs/DB11626
    Approved

    It was approved for use by the European Medicines Agency in April of 1999 for use as an adjunt to surgery for the subsequent removal of the tumor and in palliative care for irresectable soft tissue sarcoma

  6. Drug

    Cimicoxib

    go.drugbank.com/drugs/DB05095
    Investigational

    If approved, Cimicoxib would be the first drug in decades to treat depression by a new mechanism of action. … Cimicoxib is a selective COX-2 inhibitor being developed by Affectis as a treatment for depression and schizophrenia.

    Categories: Anti-Inflammatory Agents, Non-Steroidal
  7. Drug

    Umifenovir

    go.drugbank.com/drugs/DB13609
    Investigational

    [A191475,A191412] This dual activity may also confer additional protection against viral resistance, as the development of resistance to umifenovir does not appear to be significant. … [A191475] Umifenovir is currently being investigated as a potential treatment and prophylactic agent for COVID-19 caused by SARS-CoV2 infections in combination with both currently available and investigational

  8. Drug

    Olaparib

    go.drugbank.com/drugs/DB09074
    ApprovedInvestigational

    [L41100, L40908, L43792] It was first approved by the FDA and EU in December 2014,[A246020] and by Health Canada in April 2016.[L42820] … [L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell

  9. Drug

    Nonivamide

    go.drugbank.com/drugs/DB11324
    Approved

    It is naturally found in chili peppers but manufactured to produce a synthetic form for various pharmacologic preparations [L2641].

    Synonyms: N-Vanillylnonamide, N-Nonanoyl vanillylamideMixtures: NEW AMMELTZ YOKO YOKO, NEW AMMELTZ YOKO YOKO GOLD TOPICAL LIQUID
  10. Drug

    Efgartigimod alfa

    go.drugbank.com/drugs/DB15270
    ApprovedInvestigational

    Myasthenia gravis (MG) is an autoimmune disorder characterized by significant muscle weakness - particularly in the eye, throat, and extremities - caused by autoantibodies attacking the neuromuscular junction … [L39509] By antagonizing this interaction, efgartigimod alfa prevents this recycling phase and thus decreases the half-life of IgG, effectively lowering circulating levels of IgG autoantibodies against